Zymeworks shares were unchanged following the quarter, reflecting investor indifference to a steep revenue decline offset by modest improvements in expenses and advancing pipeline updates, while the widening net loss and reduced milestone income raised concerns.

• Revenue fell sharply to $2.4 million from $27.1 million year-over-year, primarily due to the absence of nonrecurring clinical milestone payments received in Q1 2025.
• Operating expenses decreased modestly to $49.5 million from $52.7 million, driven by lower R&D spend on late-stage and discontinued programs but partly offset by increased early-stage investment and leadership transition costs.
• Net loss widened to $44.2 million from $22.6 million in the prior year quarter, reflecting the revenue drop and ongoing investment in development activities.
• Advances in the pipeline include progressing regulatory and commercial milestones for zanidatamab and initial positive early-stage clinical data for ADC candidates presented at AACR.
• Management emphasized a strategic focus on integrating R&D with royalty aggregation but did not provide updated financial guidance or concrete near-term revenue visibility beyond milestone expectations.